DE60319354D1 - Mannose-6-Phosphat Rezeptor vermittelter Gentransfer zu Muskelzellen - Google Patents
Mannose-6-Phosphat Rezeptor vermittelter Gentransfer zu MuskelzellenInfo
- Publication number
- DE60319354D1 DE60319354D1 DE60319354T DE60319354T DE60319354D1 DE 60319354 D1 DE60319354 D1 DE 60319354D1 DE 60319354 T DE60319354 T DE 60319354T DE 60319354 T DE60319354 T DE 60319354T DE 60319354 D1 DE60319354 D1 DE 60319354D1
- Authority
- DE
- Germany
- Prior art keywords
- mannose
- muscle cells
- phosphate receptor
- gene transfer
- mediated gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03077205A EP1495769B1 (de) | 2003-07-11 | 2003-07-11 | Mannose-6-Phosphat Rezeptor vermittelter Gentransfer zu Muskelzellen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60319354D1 true DE60319354D1 (de) | 2008-04-10 |
| DE60319354T2 DE60319354T2 (de) | 2009-03-26 |
Family
ID=33442814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60319354T Expired - Lifetime DE60319354T2 (de) | 2003-07-11 | 2003-07-11 | Mannose-6-Phosphat Rezeptor vermittelter Gentransfer zu Muskelzellen |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1495769B1 (de) |
| AT (1) | ATE387217T1 (de) |
| DE (1) | DE60319354T2 (de) |
| DK (1) | DK1495769T3 (de) |
| ES (1) | ES2302898T3 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE498685T1 (de) | 2004-06-28 | 2011-03-15 | Univ Western Australia | Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon |
| GB0524987D0 (en) | 2005-12-08 | 2006-01-18 | Ge Healthcare Ltd | Novel imaging agents for fibrosis |
| WO2007123391A1 (en) | 2006-04-20 | 2007-11-01 | Academisch Ziekenhuis Leiden | Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene. |
| EP1857548A1 (de) | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Mittel und Verfahren zur Induktion von Exon-skipping |
| EP2049664B1 (de) | 2006-08-11 | 2011-09-14 | Prosensa Technologies B.V. | Einzelsträngige Oligonukleotide, welche komplementär zu repetitiven Elementen sind, zur Behandlung von DNS-Wiederholungen-Instabilitäts-assoziierten Erkrankungen |
| WO2009008725A2 (en) | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
| NZ582521A (en) | 2007-07-12 | 2011-09-30 | Prosensa Technologies Bv | A conjugate comprising the amino acid sequence LGAQSNF for targeting compounds to muscle tissue |
| USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
| DK2203173T3 (en) | 2007-10-26 | 2016-02-29 | Academisch Ziekenhuis Leiden | Materials and methods for prevention of muscle diseases |
| NZ587178A (en) | 2008-02-08 | 2011-11-25 | Prosensa Holding Bv | Methods and means for treating dna repeat instability associated genetic disorders |
| EP2119783A1 (de) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel |
| CN102203253B (zh) | 2008-10-24 | 2016-04-06 | 萨雷普塔治疗公司 | 用于dmd的多外显子跳跃组合物 |
| WO2010123369A1 (en) | 2009-04-24 | 2010-10-28 | Prosensa Technologies B.V. | Oligonucleotide comprising an inosine for treating dmd |
| ES2576853T3 (es) | 2009-07-03 | 2016-07-11 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Compuestos dirigidos al receptor del manosa 6-fosfato independiente de cationes |
| KR102113306B1 (ko) | 2009-11-12 | 2020-05-21 | 더 유니버시티 오브 웨스턴 오스트레일리아 | 안티센스 분자 및 이를 이용한 질환 치료방법 |
| AU2010335039B2 (en) | 2009-12-24 | 2015-03-26 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Molecule for treating an inflammatory disorder |
| CN104203289B (zh) | 2012-01-27 | 2020-11-03 | 比奥马林技术公司 | 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸 |
| CN104918639B (zh) * | 2012-10-22 | 2018-01-26 | 萨拜格Rfa公司 | 用于将治疗剂递送到活细胞和细胞核中的*** |
| CN104884618A (zh) | 2012-11-15 | 2015-09-02 | 罗氏创新中心哥本哈根有限公司 | 寡核苷酸缀合物 |
| WO2014118272A1 (en) | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Antimir-122 oligonucleotide carbohydrate conjugates |
| CA2893801A1 (en) | 2013-01-30 | 2014-08-07 | F. Hoffmann-La Roche Ag | Lna oligonucleotide carbohydrate conjugates |
| EA035882B1 (ru) | 2013-03-14 | 2020-08-27 | Сарепта Терапьютикс, Инк. | Антисмысловые олигонуклеотиды, обеспечивающие пропуск экзонов, для лечения мышечной дистрофии |
| WO2014144978A2 (en) | 2013-03-15 | 2014-09-18 | Sarepta Therapeutics, Inc. | Improved compositions for treating muscular dystrophy |
| EP3591054A1 (de) | 2013-06-27 | 2020-01-08 | Roche Innovation Center Copenhagen A/S | Gegen pcsk9 gerichtete antisense-oligomere und konjugate |
| GB201408623D0 (en) | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
| UA127432C2 (uk) | 2016-03-14 | 2023-08-23 | Ф. Хоффманн-Ля Рош Аг | Олігонуклеотид для зниження експресії pd-l1 |
| CN113474633A (zh) | 2019-02-26 | 2021-10-01 | 罗氏创新中心哥本哈根有限公司 | 寡核苷酸配制方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6172208B1 (en) * | 1992-07-06 | 2001-01-09 | Genzyme Corporation | Oligonucleotides modified with conjugate groups |
-
2003
- 2003-07-11 DK DK03077205T patent/DK1495769T3/da active
- 2003-07-11 ES ES03077205T patent/ES2302898T3/es not_active Expired - Lifetime
- 2003-07-11 DE DE60319354T patent/DE60319354T2/de not_active Expired - Lifetime
- 2003-07-11 EP EP03077205A patent/EP1495769B1/de not_active Expired - Lifetime
- 2003-07-11 AT AT03077205T patent/ATE387217T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE387217T1 (de) | 2008-03-15 |
| DK1495769T3 (da) | 2008-06-23 |
| DE60319354T2 (de) | 2009-03-26 |
| ES2302898T3 (es) | 2008-08-01 |
| EP1495769B1 (de) | 2008-02-27 |
| EP1495769A1 (de) | 2005-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60319354D1 (de) | Mannose-6-Phosphat Rezeptor vermittelter Gentransfer zu Muskelzellen | |
| EP1191098A3 (de) | Pharmazeutische Zusammensetzung zur Behandlung von Duchenne-Muskeldystrophie | |
| EP3284823A3 (de) | Verfahren für effizientes exon-(44)-skipping bei duchenne-muskeldystrophie und zugehörige mittel | |
| Arzumanov et al. | Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2 ‘-O-methyl/LNA oligoribonucleotides | |
| Sugiyama et al. | Chiral peptide nucleic acids with a substituent in the N-(2-aminoethy) glycine backbone | |
| JP2005500025A5 (de) | ||
| GB0307803D0 (en) | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two | |
| IL164637A0 (en) | Vaginal care compositions containing viable microorganisms | |
| SI1670828T1 (sl) | Kompletna humana protitelesa protu humanem 4-1bb (cd137) | |
| YU6502A (sh) | Usmeravanje multimernih agenasa za dobijanje kontrasta pri dijagnostičkom snimanju putem multilokusnog vezivanja | |
| IL212509A (en) | Antisense oligonucleotides and their use to induce exon 52 in the human duchenne dystrophy muscular duchenne gene | |
| DK1756259T3 (da) | Reaktorsystem med omrørt beholder | |
| ATE391134T1 (de) | Oligonukleotid n3'-p5' thiophosphoramidate: ihre synthese und verwendung | |
| Brigg et al. | Novel indole sulfides as potent HIV-1 NNRTIs | |
| Kiviniemi et al. | Synthesis of aminoglycoside-3′-conjugates of 2′-O-methyl oligoribonucleotides and their invasion to a 19F labeled HIV-1 TAR model | |
| EP1736501A4 (de) | Peg-funktionelles nucleinsäurekonjugat | |
| EP1892293A4 (de) | Transkriptionsfaktorköder | |
| ZA200805703B (en) | Preparation of pharmaceutical salts of 3-0-(3',3'-dimethyl-succinyl) betulinic acid | |
| Lundin et al. | Increased stability and specificity through combined hybridization of peptide nucleic acid (PNA) and locked nucleic acid (LNA) to supercoiled plasmids for PNA-anchored “Bioplex” formation | |
| IL149599A0 (en) | Use of disease-associated gene | |
| Hu et al. | Cellular localization and allele-selective inhibition of mutant huntingtin protein by peptide nucleic acid oligomers containing the fluorescent nucleobase [bis-o-(aminoethoxy) phenyl] pyrrolocytosine | |
| Khim et al. | Discovery of novel and potent aryl diamines as leukotriene A4 hydrolase inhibitors | |
| WO2005072053A9 (en) | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of colon cancer | |
| EP1129725A3 (de) | Oligonukleotid-Konjugate | |
| JP2003508618A5 (de) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |